Earticle

초록

영어

Human breast milk contains full of bioactive components to support the healthy growth and development of newborn babies in their early stage of life. These bioactive components are consisted of essential microbes, human milk oligosaccharides (HMOs), immunoglobulins, lactoferrin, cytokines, and fatty acids. These factors harmonize with gut bacteria to establish the intestinal microbiome of babies. Human milk oligosaccharides (HMOs) are the third most abundant solid components after lactose and lipids. The structural nature of HMOs are complex mixtures of unconjugated glycans with backbone of lactose linked with fucose, sialic acids and/or N-acetyl glucosamine. HMOs are known to have over 200 derivatives resulting from the combination of sugar moiety and linkages. There have been intensive studies on the utilization of HMOs by gut microbiota. Bifidobacterium species are actively involved in the digestion of major HMOs compounds. B. infantis, B. longum, B. breve, and B. bifidum are well known Bifidobacterium species equipped with the enzymes required for the digestion of complex glycans of mother's milk. There is a strong evidence that the establishment of a healthy microbiome in neonates are very crucial for the immune development and prevention of pathogen infections. HMOs are specific and selective prebiotics for Bifidobacterium and play major roles for the growth of B. infantis in the newborn babies' intestine. Potentials of HMOs as antivirals are being studied in several research groups. It is considered that HMOs may mimic structures of viral receptors and block adherence to target cells thus preventing infection. Some of recent review on the glycan binding studies for several viruses will be introduced briefly. Advanced Protein Technologies Corporation (APTech) is working on the development of series of major HMOs. APTech is operating HMO manufacturing plant in Hwasung city for the production of 2’-fucosyllactose (2’-FL). The company got FSSC22000 certificate in October, 2020. APTech is expecting the approval of 2’-FL as food ingredient in Korea and US FDA GRAS notification early next year. EU novel food application is also underway and will be finalized within 2021. References 1. Wicinski M., Sawicka E., Gebalski J., Kubiak K., and Malinowski B., Human Milk Oligosaccharides: Health Benefits, Potential Applications in Infant Formulas, and Pharmacology (2020), Nutrients 12(1):266 2. Sakanaka M., Gotoh A., Yoshida K., Odamaki T., Koguchi H., Xiao J., Kitaoka M. and Katayama T., Varied Pathways of Infant Gut-Associated Bifidobactirium to Assimilate Human Milk Oligosaccharides: Prevalence of the Gene Set and Its Correlation with Bifidobacteria-Rich Microbiota Formation (2020), Nutrients 12 (1):71 3. Morozov V., Hansman G., Hanisch F., Schroten H. and Kunz C., Human milk oligosaccharides as promising antivirals (2018), Mol Nutr Food Res 62(6): 1700679

키워드

저자

• 윤종원 [ Jong-Won Yoon | ㈜에이피테크놀로지 연구소장/부사장 ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국당과학회 학술대회

• 간기

  연간

• 수록기간

  2006~2022

• 십진분류

  KDC 517 DDC 614